Superior Progression-Free Survival Associated with Continuous Targeted Therapy Combination for BRAF-mutated Melanoma
Rutgers Cancer Institute of New JerseyResults from a randomized phase 2 clinical trial examining the targeted therapy drugs dabrafenib and tremetinib in both continuous and intermittent treatment of patients with BRAF-mutated melanoma show continuous dosing yields superior progression free survival. A Rutgers Cancer Institute of New Jersey investigator shares more on the work presented at the opening plenary session of the virtual AACR Annual Meeting.